KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Cost of RevenueEBIATGross ProfitLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsReceivables - NetReceivables - OtherShares IssuedShares OutstandingShares Outstanding
Ratios

Nektar Therapeutics (NKTR) Accumulated Depreciation & Amortization (2016 - 2024)

Nektar Therapeutics has reported Accumulated Depreciation & Amortization over the past 10 years, most recently at $4.1 million for Q4 2024.

  • Quarterly results put Accumulated Depreciation & Amortization at $4.1 million for Q4 2024, down 41.43% from a year ago — trailing twelve months through Dec 2024 was $4.1 million (down 41.43% YoY), and the annual figure for FY2024 was $4.1 million, down 41.43%.
  • Accumulated Depreciation & Amortization for Q4 2024 was $4.1 million at Nektar Therapeutics, down from $7.0 million in the prior quarter.
  • Over the last five years, Accumulated Depreciation & Amortization for NKTR hit a ceiling of $13.0 million in Q4 2021 and a floor of -$11.4 million in Q2 2022.
  • Median Accumulated Depreciation & Amortization over the past 5 years was $7.0 million (2023), compared with a mean of $4.1 million.
  • Biggest five-year swings in Accumulated Depreciation & Amortization: grew 13.64% in 2020 and later tumbled 42.62% in 2023.
  • Nektar Therapeutics' Accumulated Depreciation & Amortization stood at $12.5 million in 2020, then grew by 4.0% to $13.0 million in 2021, then dropped by 6.15% to $12.2 million in 2022, then plummeted by 42.62% to $7.0 million in 2023, then plummeted by 41.43% to $4.1 million in 2024.
  • The last three reported values for Accumulated Depreciation & Amortization were $4.1 million (Q4 2024), $7.0 million (Q4 2023), and $12.2 million (Q4 2022) per Business Quant data.